New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol 1996;134:352-6. Pyridostigmine (PD), a muscarinic cholinergic agonist, and arginine (ARG) clearly increase the growth hormone (GH) response to growth hormone-releasing hormone (GHRH) 
The diagnosis of growth hormone (GH) deficiency (GHD) in childhood is based on auxological and hormonal investigations, whereas this diagnosis in adults is based on hormonal investigations only, i.e. the assessment of serum insulin-like growth factor I (IGF-I) and serum IGF binding protein 3 and the testing of GH secretion after pharmacological stimuli, spontaneous GH secretion or a combination of both. However, there is no consensus as to which test or combination of tests should be used to assess GH status.
The ready availability of recombinant human GH has led to many studies of the biological consequences of GH deficiency and the benefits of treating adults with this drug. To date, several studies in GH-deficient adults report a beneficial effect of GH treatment on body composition and cardiovascular and musculoskeletal function (1) (2) (3) (4) (5) . Thus We have reported previously (7) (8) (9) that pyridostigmine (PD), a muscarinic cholinergic agonist, and arginine (ARG) clearly increase, both in children and in adults, the GH response to GH-releasing hormone (GHRH). In contrast to GHRH alone (10) (Fig. 4) . insulin-induced hypoglycaemia (median 1.2pg/i; range 0.2-5.9 µg/l) (Fig. 4) . Arginine, but not pyridostigmine, is able to restore totally the reduced GH responsiveness to GHRH in elderly subjects, making it overlap with that in young adults (19, 20 
